These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
329 related articles for article (PubMed ID: 27918718)
1. Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O Cloughesy T; Finocchiaro G; Belda-Iniesta C; Recht L; Brandes AA; Pineda E; Mikkelsen T; Chinot OL; Balana C; Macdonald DR; Westphal M; Hopkins K; Weller M; Bais C; Sandmann T; Bruey JM; Koeppen H; Liu B; Verret W; Phan SC; Shames DS J Clin Oncol; 2017 Jan; 35(3):343-351. PubMed ID: 27918718 [TBL] [Abstract][Full Text] [Related]
2. Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial. Herrlinger U; Schäfer N; Steinbach JP; Weyerbrock A; Hau P; Goldbrunner R; Friedrich F; Rohde V; Ringel F; Schlegel U; Sabel M; Ronellenfitsch MW; Uhl M; Maciaczyk J; Grau S; Schnell O; Hänel M; Krex D; Vajkoczy P; Gerlach R; Kortmann RD; Mehdorn M; Tüttenberg J; Mayer-Steinacker R; Fietkau R; Brehmer S; Mack F; Stuplich M; Kebir S; Kohnen R; Dunkl E; Leutgeb B; Proescholdt M; Pietsch T; Urbach H; Belka C; Stummer W; Glas M J Clin Oncol; 2016 May; 34(14):1611-9. PubMed ID: 26976423 [TBL] [Abstract][Full Text] [Related]
3. Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial. Reardon DA; Brandes AA; Omuro A; Mulholland P; Lim M; Wick A; Baehring J; Ahluwalia MS; Roth P; Bähr O; Phuphanich S; Sepulveda JM; De Souza P; Sahebjam S; Carleton M; Tatsuoka K; Taitt C; Zwirtes R; Sampson J; Weller M JAMA Oncol; 2020 Jul; 6(7):1003-1010. PubMed ID: 32437507 [TBL] [Abstract][Full Text] [Related]
4. Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study. Nabors LB; Fink KL; Mikkelsen T; Grujicic D; Tarnawski R; Nam DH; Mazurkiewicz M; Salacz M; Ashby L; Zagonel V; Depenni R; Perry JR; Hicking C; Picard M; Hegi ME; Lhermitte B; Reardon DA Neuro Oncol; 2015 May; 17(5):708-17. PubMed ID: 25762461 [TBL] [Abstract][Full Text] [Related]
5. A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma. Brandes AA; Gil-Gil M; Saran F; Carpentier AF; Nowak AK; Mason W; Zagonel V; Dubois F; Finocchiaro G; Fountzilas G; Cernea DM; Chinot O; Anghel R; Ghiringhelli F; Beauchesne P; Lombardi G; Franceschi E; Makrutzki M; Mpofu C; Urban HJ; Pichler J Oncologist; 2019 Apr; 24(4):521-528. PubMed ID: 30266892 [TBL] [Abstract][Full Text] [Related]
7. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Stupp R; Hegi ME; Gorlia T; Erridge SC; Perry J; Hong YK; Aldape KD; Lhermitte B; Pietsch T; Grujicic D; Steinbach JP; Wick W; Tarnawski R; Nam DH; Hau P; Weyerbrock A; Taphoorn MJ; Shen CC; Rao N; Thurzo L; Herrlinger U; Gupta T; Kortmann RD; Adamska K; McBain C; Brandes AA; Tonn JC; Schnell O; Wiegel T; Kim CY; Nabors LB; Reardon DA; van den Bent MJ; Hicking C; Markivskyy A; Picard M; Weller M; ; ; Lancet Oncol; 2014 Sep; 15(10):1100-8. PubMed ID: 25163906 [TBL] [Abstract][Full Text] [Related]
8. MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial. Weller M; Tabatabai G; Kästner B; Felsberg J; Steinbach JP; Wick A; Schnell O; Hau P; Herrlinger U; Sabel MC; Wirsching HG; Ketter R; Bähr O; Platten M; Tonn JC; Schlegel U; Marosi C; Goldbrunner R; Stupp R; Homicsko K; Pichler J; Nikkhah G; Meixensberger J; Vajkoczy P; Kollias S; Hüsing J; Reifenberger G; Wick W; Clin Cancer Res; 2015 May; 21(9):2057-64. PubMed ID: 25655102 [TBL] [Abstract][Full Text] [Related]
9. Bevacizumab versus alkylating chemotherapy in recurrent glioblastoma. Seystahl K; Hentschel B; Loew S; Gramatzki D; Felsberg J; Herrlinger U; Westphal M; Schackert G; Thon N; Tatagiba M; Pietsch T; Reifenberger G; Löffler M; Wick W; Weller M; J Cancer Res Clin Oncol; 2020 Mar; 146(3):659-670. PubMed ID: 31754832 [TBL] [Abstract][Full Text] [Related]
10. Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma. Schäfer N; Proescholdt M; Steinbach JP; Weyerbrock A; Hau P; Grauer O; Goldbrunner R; Friedrich F; Rohde V; Ringel F; Schlegel U; Sabel M; Ronellenfitsch MW; Uhl M; Grau S; Hänel M; Schnell O; Krex D; Vajkoczy P; Tabatabai G; Mack F; Schaub C; Tzaridis T; Nießen M; Kebir S; Leutgeb B; Urbach H; Belka C; Stummer W; Glas M; Herrlinger U Neuro Oncol; 2018 Jun; 20(7):975-985. PubMed ID: 29121274 [TBL] [Abstract][Full Text] [Related]
11. O(6)-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma. Sonoda Y; Yokosawa M; Saito R; Kanamori M; Yamashita Y; Kumabe T; Watanabe M; Tominaga T Int J Clin Oncol; 2010 Aug; 15(4):352-8. PubMed ID: 20232102 [TBL] [Abstract][Full Text] [Related]
12. Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial†. Pujol JL; Lavole A; Quoix E; Molinier O; Souquet PJ; Barlesi F; Le Caer H; Moro-Sibilot D; Fournel P; Oster JP; Chatellain P; Barre P; Jeannin G; Mourlanette P; Derollez M; Herman D; Renault A; Dayen C; Lamy PJ; Langlais A; Morin F; Zalcman G; Ann Oncol; 2015 May; 26(5):908-914. PubMed ID: 25688059 [TBL] [Abstract][Full Text] [Related]
13. A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer. Bendell JC; Hochster H; Hart LL; Firdaus I; Mace JR; McFarlane JJ; Kozloff M; Catenacci D; Hsu JJ; Hack SP; Shames DS; Phan SC; Koeppen H; Cohn AL Oncologist; 2017 Mar; 22(3):264-271. PubMed ID: 28209746 [TBL] [Abstract][Full Text] [Related]
14. Randomized, phase II, placebo-controlled trial of onartuzumab and/or bevacizumab in combination with weekly paclitaxel in patients with metastatic triple-negative breast cancer. Diéras V; Campone M; Yardley DA; Romieu G; Valero V; Isakoff SJ; Koeppen H; Wilson TR; Xiao Y; Shames DS; Mocci S; Chen M; Schmid P Ann Oncol; 2015 Sep; 26(9):1904-1910. PubMed ID: 26202594 [TBL] [Abstract][Full Text] [Related]
15. Third-line therapy in recurrent glioblastoma: is it another chance for bevacizumab? Franceschi E; Lamberti G; Paccapelo A; Di Battista M; Genestreti G; Minichillo S; Mura A; Bartolini S; Agati R; Brandes AA J Neurooncol; 2018 Sep; 139(2):383-388. PubMed ID: 29671196 [TBL] [Abstract][Full Text] [Related]
16. Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma. Lassen U; Chinot OL; McBain C; Mau-Sørensen M; Larsen VA; Barrie M; Roth P; Krieter O; Wang K; Habben K; Tessier J; Lahr A; Weller M Neuro Oncol; 2015 Jul; 17(7):1007-15. PubMed ID: 25665807 [TBL] [Abstract][Full Text] [Related]
17. Predictive impact of MGMT promoter methylation in glioblastoma of the elderly. Reifenberger G; Hentschel B; Felsberg J; Schackert G; Simon M; Schnell O; Westphal M; Wick W; Pietsch T; Loeffler M; Weller M; Int J Cancer; 2012 Sep; 131(6):1342-50. PubMed ID: 22139906 [TBL] [Abstract][Full Text] [Related]
18. Procarbazine and CCNU Chemotherapy for Recurrent Glioblastoma with MGMT Promoter Methylation. Kim SH; Yoo H; Chang JH; Kim CY; Chung DS; Kim SH; Park SH; Lee YS; Yang SH J Korean Med Sci; 2018 Jun; 33(24):e167. PubMed ID: 29892208 [TBL] [Abstract][Full Text] [Related]
19. The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials. Binabaj MM; Bahrami A; ShahidSales S; Joodi M; Joudi Mashhad M; Hassanian SM; Anvari K; Avan A J Cell Physiol; 2018 Jan; 233(1):378-386. PubMed ID: 28266716 [TBL] [Abstract][Full Text] [Related]
20. The added value of bevacizumab concomitantly administered with carboplatin versus carboplatin alone in patients with recurrent glioblastomas. Kaloshi G; Diamandi P; Cakani B; Brace G; Rroji A; Petrela M Tumori; 2015; 101(1):41-5. PubMed ID: 25702676 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]